Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies
NCT: NCT02753517 · COMPLETED
Brief Summary
Extended hepatectomies of 4 or more segments are complicated by high rates of morbidity and mortality, mainly related to hepatic liver failure. Nowadays, preoperative assessment of the future remnant liver is just performed through its volumetric measurement by computed tomography. Nevertheless, this volumetric assessment does not reflect the hepatocellular function of the future remnant liver that can be disturbed in case of vascular and/or biliary obstruction, chemotherapy-induced liver injuries or steatosis in overweight patients. Literature data (albeit originating from a single centre in Europe) have suggested that (99m)Tc-mebrofenin hepatobiliary scintigraphy could be useful in evaluating the function of the future remnant liver. The aim of this prospective multicentric study is to determine the predictive value of hepatobiliary scintigraphy in assessing the risk of postoperative liver failure of extended hepatectomies of 4 or more segments in noncirrhotic liver.
Frequently Asked Questions
What is Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies?
Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies is a clinical trial registered under NCT02753517. Current status: COMPLETED.
What is the status of NCT02753517?
The current status of NCT02753517 (Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies) is: COMPLETED.
When did Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies start?
Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies started on 2015-12-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.